Mazuecos A, Rodriguez Benot A, Moreno A, Burgos D, Aguera M, Garcia Alvarez T, Hernandez D, Navarro D, Castro P
Department of Nephrology, Hospital Puerta del Mar, Cadiz, Spain.
Transplant Proc. 2012 Sep;44(7):2053-6. doi: 10.1016/j.transproceed.2012.07.082.
The prognosis of HIV infection has improved dramatically in patients with end-stage renal disease (ESRD). Thus, HIV infection is no longer an absolute contraindication for renal transplantation.
A cross-sectional study was performed to analyze the characteristics of HIV patients receiving renal replacement therapy (RRT) in September 2011, using data from the Registry of Renal Patients in Andalusia. A retrospective cohort study was also carried out, analyzing patients receiving kidney transplants in the era of highly active antiretroviral therapy.
In Andalusia in September 2011, 8744 patients were on RRT; of these, 48 had HIV infection (prevalence 0.54%). The RRT modality was very different between HIV-negative and HIV-positive patients: renal transplantation 49.2% and 16.7%, hemodialysis 46.8% and 81.3%, and peritoneal dialysis 4% and 2%, respectively. The most frequent ESRD etiology was glomerulonephritis (37.5%). Twenty-seven (56.3%) had hepatitis C coinfection. Only three patients (7.5%) were on the waiting list for renal transplantation. From 2001 to September 2011, 10 HIV-infected patients received a renal transplantation (median follow-up 40.5 months). The initial immunosuppressive treatment included tacrolimus and mycophenolate without induction therapy. Only two patients presented acute rejection, both borderline and corticosensitive. All remain alive and the graft survival was 100% in the first and third years posttransplant. We compared demographic and comorbidity variables between patients transplanted or included on the waiting list (n = 12) and patients excluded and never transplanted (n = 36). We found differences only in the ESRD etiology (higher incidence of glomerulonephritis in excluded patients).
Renal transplantation is safe in correctly selected HIV-infected patients. The number of patients on the waiting list is very small. This may reflect the high comorbidity but it is also possible that these patients are still not being assessed systematically for transplant in all centers.
终末期肾病(ESRD)患者中,HIV感染的预后已显著改善。因此,HIV感染不再是肾移植的绝对禁忌证。
利用安达卢西亚肾病患者登记处的数据,进行了一项横断面研究,以分析2011年9月接受肾脏替代治疗(RRT)的HIV患者的特征。还开展了一项回顾性队列研究,分析在高效抗逆转录病毒治疗时代接受肾移植的患者。
2011年9月在安达卢西亚,8744例患者接受RRT;其中48例感染HIV(患病率0.54%)。HIV阴性和HIV阳性患者的RRT方式差异很大:肾移植分别为49.2%和16.7%,血液透析分别为46.8%和81.3%,腹膜透析分别为4%和2%。最常见的ESRD病因是肾小球肾炎(37.5%)。27例(56.3%)合并丙型肝炎感染。只有3例患者(7.5%)在等待肾移植名单上。从2001年到2011年9月,10例HIV感染患者接受了肾移植(中位随访40.5个月)。初始免疫抑制治疗包括他克莫司和霉酚酸,无诱导治疗。仅2例患者出现急性排斥反应,均为临界性且对皮质激素敏感。所有患者均存活,移植后第一年和第三年的移植物存活率均为100%。我们比较了移植或列入等待名单的患者(n = 12)与被排除且从未接受移植的患者(n = 36)之间的人口统计学和合并症变量。我们仅在ESRD病因方面发现差异(被排除患者中肾小球肾炎的发生率较高)。
在正确选择的HIV感染患者中,肾移植是安全的。等待名单上的患者数量非常少。这可能反映了高合并症情况,但也有可能在所有中心这些患者仍未得到系统的移植评估。